Additionally, the presence of TP53 mutations in AML patients who receive anthracycline- and cytarabine-based induction chemotherapy has been previously associated with inferior outcomes, with reported initial response rates of 20–30% and poor OS of less than a year [4,5]. This evidence concerns the gene TP53 and acute myeloid leukemia.